PARP1 and glioblastoma: Zmuda et al. also demonstrated in a subcutaneous U87MG-Luc2 glioblastoma xenograft model (WHO grade IV) the ability of [123I]-I2-PARPi to be retained within tumour tissue and correlated this uptake to the expression of PARP and the proliferative marker Ki67 [85].